Our Pricing

Wegovy UK Availability: Begin Your Journey From £69.00

Published on: June 03, 2026

Searching for accurate wegovy uk availability price information? Wegovy (semaglutide) is now available at Cured Pharmacy from £79.00, with stock levels maintained through our UK-licensed supply chain. As a GPhC-registered pharmacy, we provide transparent pricing before consultation and same-day prescriber assessment for eligible patients.

Current Wegovy UK Availability and Stock Status

Wegovy has experienced significant supply challenges across UK pharmacies since its initial launch, but availability has stabilised considerably throughout 2024. At Cured Pharmacy, we maintain consistent stock of all Wegovy dose strengths (0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg) through our established relationships with UK-licensed wholesalers [1].

The MHRA-licensed semaglutide injection is now accessible through online pharmacy services, eliminating the need for in-person GP appointments. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees clinical governance to ensure every patient receives appropriate assessment before dispensing. Subject to prescriber approval, most patients receive their first prescription within 24 hours of completing the online consultation.

Unlike some pharmacy services that show pricing only after consultation, we display transparent costs upfront. Wegovy starts from £79.00 at Cured Pharmacy, representing competitive UK pricing for genuine, UK-licensed medication with full regulatory approval.

How Wegovy (Semaglutide) Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone your body produces after eating. This medication works through three primary mechanisms: it slows gastric emptying to prolong feelings of fullness, reduces appetite signals in the brain, and helps regulate blood glucose levels [2].

The STEP clinical trial programme demonstrated remarkable efficacy. In the landmark STEP 1 trial, participants using semaglutide 2.4mg weekly achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [2]. These results represent some of the most significant weight loss outcomes seen in pharmaceutical trials for obesity treatment.

Wegovy is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. The treatment follows a gradual dose escalation schedule over 16-20 weeks, starting at 0.25mg and increasing to the maintenance dose of 2.4mg weekly. This titration approach, overseen by your UK prescriber, helps minimise gastrointestinal side effects whilst your body adjusts to the medication [1][2].

Who Can Use Wegovy in the UK?

NICE guidelines support semaglutide use for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [3]. Your UK prescriber will assess your complete medical history, current medications, and weight loss goals during the online consultation to determine suitability.

Wegovy Pricing and Prescription Process at Cured Pharmacy

At Cured Pharmacy, Wegovy is available from £79.00, with final pricing determined by your prescribed dose strength. We guarantee the lowest prices in the UK for genuine, MHRA-licensed medication. Our transparent pricing model means you see exact costs before beginning your clinical assessment.

The prescription process is straightforward and completed entirely online. You'll complete a comprehensive medical questionnaire covering your weight history, current health conditions, medications, and lifestyle factors. This typically takes under 3 minutes. A UK-registered prescriber reviews your assessment the same day, and if approved, your prescription is issued electronically to our dispensary.

All Wegovy prescriptions include ongoing clinical support. Your prescriber may schedule follow-up assessments to monitor progress, adjust dosing, or address any concerns. Every medication is dispensed in 100% discreet packaging with no external pharmacy branding, delivered via tracked courier to your preferred address.

Payment and Delivery Options

We accept all major payment methods and offer flexible delivery scheduling. Standard delivery is free on orders over a specified threshold, with next-day and weekend delivery options available. Your medication arrives in temperature-controlled packaging to maintain semaglutide stability throughout transit.

Wegovy Side Effects and Safety Considerations

As with any prescription medication, Wegovy may cause side effects, though not everyone experiences them. The most common adverse effects are gastrointestinal: nausea, diarrhoea, vomiting, constipation, and abdominal discomfort. These symptoms typically occur during dose escalation and often diminish as your body adjusts to the medication [2].

In clinical trials, approximately 7% of participants discontinued semaglutide due to gastrointestinal side effects [2]. To minimise these effects, your prescriber will recommend starting with smaller portions at meals, eating slowly, avoiding high-fat foods, and staying well-hydrated. The gradual dose titration schedule is specifically designed to improve tolerability.

Serious side effects are rare but require immediate medical attention. These include signs of pancreatitis (severe abdominal pain radiating to the back), gallbladder problems, kidney issues, or allergic reactions. Wegovy carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans [1]. Your prescriber will screen for personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 before prescribing.

Wegovy is contraindicated in pregnancy, and effective contraception is recommended for women of childbearing potential. If you're planning pregnancy, your prescriber will advise discontinuing semaglutide at least 2 months before conception due to the medication's long half-life.

Wegovy vs Alternative Weight Loss Treatments

Several prescription weight loss medications are licensed in the UK, each with distinct mechanisms and clinical profiles. Understanding these differences helps you and your prescriber select the most appropriate treatment for your circumstances.

Semaglutide (Wegovy) and tirzepatide represent the newest generation of weight loss medications, both working through GLP-1 receptor pathways. Tirzepatide additionally activates GIP receptors, which may contribute to enhanced efficacy in some patients. Liraglutide, marketed under a different brand name, is a daily GLP-1 injection that preceded weekly semaglutide but generally produces more modest weight loss.

Oral medications remain available for patients who prefer non-injectable options. These include lipase inhibitors that reduce fat absorption and combination medications affecting appetite and metabolism. However, clinical trial data consistently shows GLP-1 receptor agonists like semaglutide produce superior weight loss outcomes compared to oral alternatives [4].

Your UK prescriber considers multiple factors when recommending treatment: your weight loss goals, medical history, previous medication responses, injection tolerance, and cost considerations. Some patients begin with one medication and transition to another based on efficacy and tolerability. This personalised approach, supported by regular clinical review, optimises outcomes whilst managing potential side effects.

Combining Wegovy with Lifestyle Modifications

Wegovy is most effective when combined with a reduced-calorie diet and increased physical activity. Clinical trials demonstrating significant weight loss included lifestyle intervention programmes alongside medication [2]. Your prescriber may recommend working with a dietitian or weight management specialist to maximise results and develop sustainable habits for long-term weight maintenance.

Long-Term Use and Maintaining Weight Loss with Wegovy

Wegovy is designed for chronic weight management rather than short-term use. Clinical data from the STEP trials followed participants for up to 104 weeks, demonstrating sustained weight loss with continued semaglutide treatment [2]. However, studies also show that discontinuing the medication often leads to weight regain, highlighting the importance of viewing this as a long-term therapy rather than a temporary intervention [5].

The STEP 4 trial specifically examined what happens when patients stop Wegovy after achieving weight loss. Participants who discontinued semaglutide regained approximately two-thirds of their lost weight over the following year, whilst those continuing treatment maintained their weight loss [5]. This evidence supports ongoing treatment for patients who respond well to semaglutide and tolerate it without significant adverse effects.

At Cured Pharmacy, we support long-term treatment through convenient repeat prescription services. Once you're established on a stable Wegovy dose, you can set up automatic refills to ensure uninterrupted treatment. Your UK prescriber conducts periodic reviews to assess ongoing suitability, monitor for complications, and adjust treatment as needed. Subject to clinical assessment, most patients continue Wegovy as long as they're achieving meaningful weight loss or maintenance without unacceptable side effects.

Cost considerations for long-term use are important. At £79.00 starting price, Wegovy represents a significant ongoing investment in your health. We're committed to maintaining the lowest UK prices and transparent pricing throughout your treatment journey. Some patients may qualify for NHS prescription support depending on their circumstances, though availability varies by region and clinical commissioning group guidelines.

Scientific References

1. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
4. Khera, R., et al. (2016). Association of Pharmacological Treatments for Obesity with Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA, 315(22), 2424–2434. https://doi.org/10.1001/jama.2016.7602 [accessed 13 August 2026]
5. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals, and outcomes cannot be guaranteed. Wegovy is a prescription-only medicine and must be used under medical supervision.